Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease.
ADPKD
biomarkers
chronic inflammation
cystic kidney disease
disease stratification
glomerular filtration rate
polycystic kidney disease
prognosis
pyuria
rapid progression
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
31 03 2022
31 03 2022
Historique:
received:
29
06
2021
accepted:
06
12
2021
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
Autosomal dominant polycystic kidney disease (ADPKD) has phenotypic variability only partially explained by established biomarkers that do not readily assess pathologically important factors of inflammation and kidney fibrosis. We evaluated asymptomatic pyuria (AP), a surrogate marker of inflammation, as a biomarker for disease progression. We performed a retrospective cohort study of adult patients with ADPKD. Patients were divided into AP and no pyuria (NP) groups. We evaluated the effect of pyuria on kidney function and kidney volume. Longitudinal models evaluating kidney function and kidney volume rate of change with respect to incidences of AP were created. There were 687 included patients (347 AP, 340 NP). The AP group had more women (65% versus 49%). Median ages at kidney failure were 86 and 80 years in the NP and AP groups (log rank, AP is associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene, cystic burden, and cystic growth. These results support AP as an enriching prognostic biomarker for the rate of disease progression.
Sections du résumé
Background
Autosomal dominant polycystic kidney disease (ADPKD) has phenotypic variability only partially explained by established biomarkers that do not readily assess pathologically important factors of inflammation and kidney fibrosis. We evaluated asymptomatic pyuria (AP), a surrogate marker of inflammation, as a biomarker for disease progression.
Methods
We performed a retrospective cohort study of adult patients with ADPKD. Patients were divided into AP and no pyuria (NP) groups. We evaluated the effect of pyuria on kidney function and kidney volume. Longitudinal models evaluating kidney function and kidney volume rate of change with respect to incidences of AP were created.
Results
There were 687 included patients (347 AP, 340 NP). The AP group had more women (65% versus 49%). Median ages at kidney failure were 86 and 80 years in the NP and AP groups (log rank,
Conclusions
AP is associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene, cystic burden, and cystic growth. These results support AP as an enriching prognostic biomarker for the rate of disease progression.
Identifiants
pubmed: 35582184
doi: 10.34067/KID.0004292021
pii: 02200512-202203000-00011
pmc: PMC9034817
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-476Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Déclaration de conflit d'intérêts
C. Hanna reports consultancy agreements with Horizon Therapeutics and honoraria from Horizon Therapeutics. P.C. Harris reports consultancy agreements with Mitobridge, Otsuka, Regulus, and Vertex; research funding from Acceleron, Jemincare, Navitor, Otsuka Pharmaceuticals, and Palladio Biosciences; patents and inventions with Amgen, Bayer, Genzyme, GlaxoSmithKline, Millipore, Mitobridge, and Vertex; honoraria from Otsuka Pharmaceuticals and Vertex Pharmaceuticals; and serving on the clinical advisory board of Mironid. P.J. Schulte reports other interests/relationships with OxThera. S.R. Senum reports ownership interest with Marvell Technology Inc. V.E. Torres reports consultancy agreements with Acceleron Pharma, Blueprint Medicines, Mironid, Otsuka Pharmaceuticals, Palladio, Reata, and Sanofi; research funding from Blueprint Medicines, Mironid, Otsuka Pharmaceuticals, Palladio Biosciences, Reata, and Sanofi Genzyme (all preclinical trials, preclinical research, or clinical trials); honoraria from Otsuka Pharmaceuticals (to the institution); and scientific advisor or membership with Mironid, Otsuka Pharmaceuticals, and Sanofi. Z.M. Zoghby reports research funding from Kadmon Corporation. All remaining authors have nothing to disclose.
Références
Chebib FT, Torres VE: Autosomal dominant polycystic kidney disease: Core curriculum 2016. Am J Kidney Dis 67: 792–810, 2016 https://doi.org/10.1053/j.ajkd.2015.07.037
doi: 10.1053/j.ajkd.2015.07.037
Cornec-Le Gall E, Alam A, Perrone RD: Autosomal dominant polycystic kidney disease. Lancet 393: 919–935, 2019 https://doi.org/10.1016/S0140-6736(18)32782-X
doi: 10.1016/S0140-6736(18)32782-X
Shukoor SS, Vaughan LE, Edwards ME, Lavu S, Kline TL, Senum SR, Mkhaimer Y, Zaatari G, Irazabal MV, Neal R, Hogan MC, Zoghby ZM, Harris PC, Torres VE, Chebib FT: Characteristics of patients with end-stage kidney disease in ADPKD. Kidney Int Rep 6: 755–767, 2020 https://doi.org/10.1016/j.ekir.2020.12.016
doi: 10.1016/j.ekir.2020.12.016
Chebib FT, Torres VE: Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy. Am J Kidney Dis 78: 282–292, 2021 https://doi.org/10.1053/j.ajkd.2020.12.020
doi: 10.1053/j.ajkd.2020.12.020
Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S: Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 25: 2399–2418, 2014 https://doi.org/10.1681/ASN.2013111184
doi: 10.1681/ASN.2013111184
Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L, Estivill X: Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 7: 2142–2151, 1996 https://doi.org/10.1681/ASN.V7102142
doi: 10.1681/ASN.V7102142
Johnson AM, Gabow PA: Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8: 1560–1567, 1997 https://doi.org/10.1681/ASN.V8101560
doi: 10.1681/ASN.V8101560
Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353: 103–107, 1999 https://doi.org/10.1016/S0140-6736(98)03495-3
doi: 10.1016/S0140-6736(98)03495-3
Dicks E, Ravani P, Langman D, Davidson WS, Pei Y, Parfrey PS: Incident renal events and risk factors in autosomal dominant polycystic kidney disease: A population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 1: 710–717, 2006 https://doi.org/10.2215/CJN.01581105
doi: 10.2215/CJN.01581105
Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King Jr. BF, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122–2130, 2006 https://doi.org/10.1056/NEJMoa054341
doi: 10.1056/NEJMoa054341
Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW: Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study. Am J Kidney Dis 39: 1127–1134, 2002 https://doi.org/10.1053/ajkd.2002.33379
doi: 10.1053/ajkd.2002.33379
Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King Jr. BF, Glockner JF, Wetzel LH, Brummer ME, O’Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64: 1035–1045, 2003 https://doi.org/10.1046/j.1523-1755.2003.00185.x
doi: 10.1046/j.1523-1755.2003.00185.x
Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479–486, 2012 https://doi.org/10.2215/CJN.09500911
doi: 10.2215/CJN.09500911
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators: Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J Am Soc Nephrol 26: 160–172, 2015 https://doi.org/10.1681/ASN.2013101138
doi: 10.1681/ASN.2013101138
Tangri N, Hougen I, Alam A, Perrone R, McFarlane P, Pei Y: Total kidney volume as a biomarker of disease progression in autosomal dominant polycystic kidney disease. Can J Kidney Health Dis 4: 2054358117693355, 2017 https://doi.org/10.1177/2054358117693355
doi: 10.1177/2054358117693355
Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE: Polycystic kidney disease. Nat Rev Dis Primers 4: 50, 2018 https://doi.org/10.1038/s41572-018-0047-y
doi: 10.1038/s41572-018-0047-y
Mun H, Park JH: Inflammation and fibrosis in ADPKD. In: Cystogenesis, edited by Park JH, Ahn C, Singapore, Springer Singapore, 2016, pp 35–44
Ta MH, Harris DC, Rangan GK: Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton) 18: 317–330, 2013 https://doi.org/10.1111/nep.12045
doi: 10.1111/nep.12045
Zeier M, Fehrenbach P, Geberth S, Möhring K, Waldherr R, Ritz E: Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42: 1259–1265, 1992 https://doi.org/10.1038/ki.1992.413
doi: 10.1038/ki.1992.413
Karihaloo A, Koraishy F, Huen SC, Lee Y, Merrick D, Caplan MJ, Somlo S, Cantley LG: Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 22: 1809–1814, 2011 https://doi.org/10.1681/ASN.2011010084
doi: 10.1681/ASN.2011010084
Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJM, Yu A, Grantham JJ, Li X: Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J Clin Invest 125: 2399–2412, 2015 https://doi.org/10.1172/JCI80467
doi: 10.1172/JCI80467
Grantham JJ, Mulamalla S, Swenson-Fields KI: Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7: 556–566, 2011 https://doi.org/10.1038/nrneph.2011.109
doi: 10.1038/nrneph.2011.109
Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, Li R: A tumor necrosis factor-α-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 14: 863–868, 2008 https://doi.org/10.1038/nm1783
doi: 10.1038/nm1783
Swenson-Fields KI, Vivian CJ, Salah SM, Peda JD, Davis BM, van Rooijen N, Wallace DP, Fields TA: Macrophages promote polycystic kidney disease progression. Kidney Int 83: 855–864, 2013 https://doi.org/10.1038/ki.2012.446
doi: 10.1038/ki.2012.446
Song CJ, Zimmerman KA, Henke SJ, Yoder BK: Inflammation and fibrosis in polycystic kidney disease. Results Probl Cell Differ 60: 323–344, 2017 https://doi.org/10.1007/978-3-319-51436-9_12
doi: 10.1007/978-3-319-51436-9_12
Kwon YE, Oh DJ, Kim MJ, Choi HM: Prevalence and clinical characteristics of asymptomatic pyuria in chronic kidney disease. Ann Lab Med 40: 238–244, 2020 https://doi.org/10.3343/alm.2020.40.3.238
doi: 10.3343/alm.2020.40.3.238
Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D: Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20: 205–212, 2009 https://doi.org/10.1681/ASN.2008050507
doi: 10.1681/ASN.2008050507
Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309–332, 2008 https://doi.org/10.1016/j.ajic.2008.03.002
doi: 10.1016/j.ajic.2008.03.002
Hay AD, Birnie K, Busby J, Delaney B, Downing H, Dudley J, Durbaba S, Fletcher M, Harman K, Hollingworth W, Hood K, Howe R, Lawton M, Lisles C, Little P, MacGowan A, O’Brien K, Pickles T, Rumsby K, Sterne JA, Thomas-Jones E, van der Voort J, Waldron CA, Whiting P, Wootton M, Butler CC: The Diagnosis of Urinary Tract infection in Young children (DUTY): A diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. Health Technol Assess 20: 1–294, 2016 https://doi.org/10.3310/hta20510
doi: 10.3310/hta20510
Wise GJ, Schlegel PN: Sterile pyuria. N Engl J Med 372: 1048–1054, 2015 https://doi.org/10.1056/NEJMra1410052
doi: 10.1056/NEJMra1410052
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009 https://doi.org/10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006
Mayo Clinic: Imaging classification of ADPKD: A simple model for selecting patients for clinical trials. Available at: https://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754 . Accessed December 22, 2021
Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet M-P, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly J-M, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE, Harris PC; Genkyst Study Group HALT Progression of Polycystic Kidney Disease Group Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease: Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet 102: 832–844, 2018 https://doi.org/10.1016/j.ajhg.2018.03.013
doi: 10.1016/j.ajhg.2018.03.013
Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC; CRISP Consortium: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18: 2143–2160, 2007 https://doi.org/10.1681/ASN.2006121387
doi: 10.1681/ASN.2006121387
Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van’t Hoff WG, Niaudet P, Torres VE, Harris PC: Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease [published corrections appear in Kidney Int 75: 1359, 2009 and Kidney Int 77: 368, 2010]. Kidney Int 75: 848–855, 2009 https://doi.org/10.1038/ki.2008.686
doi: 10.1038/ki.2008.686
Hopp K, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui FF, Torres VE, Harris PC; HALT Progression of Polycystic Kidney Disease Group, the ADPKD Modifier Study: Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int 97: 370–382, 2020 https://doi.org/10.1016/j.kint.2019.08.038
doi: 10.1016/j.kint.2019.08.038
Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu ASL, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators: Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27: 2872–2884, 2016 https://doi.org/10.1681/ASN.2015050583
doi: 10.1681/ASN.2015050583
Lavu S, Vaughan LE, Senum SR, Kline TL, Chapman AB, Perrone RD, Mrug M, Braun WE, Steinman TI, Rahbari-Oskoui FF, Brosnahan GM, Bae KT, Landsittel D, Chebib FT, Yu ASL, Torres VE, Harris PC; HALT PKD and CRISP Study Investigators: The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight 5: e138724, 2020 https://doi.org/10.1172/jci.insight.138724
doi: 10.1172/jci.insight.138724
Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Banales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrezet MP, Ferec C, Le Meur Y, Torres VE, Harris PC; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease: Mutations in GANAB, encoding the glucosidase II alpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98: 1193–1207, 2016 https://doi.org/10.1016/j.ajhg.2016.05.004
doi: 10.1016/j.ajhg.2016.05.004
Harris PC, Torres VE: Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 124: 2315–2324, 2014 https://doi.org/10.1172/JCI72272
doi: 10.1172/JCI72272
Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K: CD8 + T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int 94: 1127–1140, 2018 https://doi.org/10.1016/j.kint.2018.06.025
doi: 10.1016/j.kint.2018.06.025
Viau A, Bienaimé F, Lukas K, Todkar AP, Knoll M, Yakulov TA, Hofherr A, Kretz O, Helmstädter M, Reichardt W, Braeg S, Aschman T, Merkle A, Pfeifer D, Dumit VI, Gubler MC, Nitschke R, Huber TB, Terzi F, Dengjel J, Grahammer F, Köttgen M, Busch H, Boerries M, Walz G, Triantafyllopoulou A, Kuehn EW: Cilia-localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney. EMBO J 37: e98615, 2018 https://doi.org/10.15252/embj.201798615
doi: 10.15252/embj.201798615
Cassini MF, Kakade VR, Kurtz E, Sulkowski P, Glazer P, Torres R, Somlo S, Cantley LG: Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 29: 2471–2481, 2018 https://doi.org/10.1681/ASN.2018050518
doi: 10.1681/ASN.2018050518
Cowley Jr. BD, Ricardo SD, Nagao S, Diamond JR: Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 60: 2087–2096, 2001 https://doi.org/10.1046/j.1523-1755.2001.00065.x
doi: 10.1046/j.1523-1755.2001.00065.x
Zheng D, Wolfe M, Cowley Jr. BD, Wallace DP, Yamaguchi T, Grantham JJ: Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 2588–2595, 2003 https://doi.org/10.1097/01.ASN.0000088720.61783.19
doi: 10.1097/01.ASN.0000088720.61783.19
Janssens P, Decuypere J-P, De Rechter S, Breysem L, Van Giel D, Billen J, Hindryckx A, De Catte L, Baldewijns M, Claes KBM, Wissing KM, Devriendt K, Bammens B, Meyts I, Torres VE, Vennekens R, Mekahli D: Enhanced MCP-1 release in early autosomal dominant polycystic kidney disease. Kidney Int Rep 6: 1687–1698, 2021 https://doi.org/10.1016/j.ekir.2021.03.893
doi: 10.1016/j.ekir.2021.03.893
Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT; on behalf of the DIPAK-1 study investigators: Rapid progression of autosomal dominant polycystic kidney disease: Urinary biomarkers as predictors. Am J Nephrol 50: 375–385, 2019 https://doi.org/10.1159/000502999
doi: 10.1159/000502999
Messchendorp AL, Meijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM, Losekoot M, Burgerhof JGM, Peters DJM, Gansevoort RT; DIPAK Consortium: Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression. Kidney Int Rep 3: 291–301, 2017 https://doi.org/10.1016/j.ekir.2017.10.004
doi: 10.1016/j.ekir.2017.10.004
Zimmerman KA, Gonzalez NM, Chumley P, Chacana T, Harrington LE, Yoder BK, Mrug M: Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease. Physiol Rep 7: e13951, 2019 https://doi.org/10.14814/phy2.13951
doi: 10.14814/phy2.13951
Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, Morin MP, Moal MC, Dantal J, Wehbe B, Perrichot R, Frouget T, Vigneau C, Potier J, Jousset P, Guillodo MP, Siohan P, Terki N, Sawadogo T, Legrand D, Menoyo-Calonge V, Benarbia S, Besnier D, Longuet H, Férec C, Le Meur Y: The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27: 942–951, 2016 https://doi.org/10.1681/ASN.2015010016
doi: 10.1681/ASN.2015010016
Schwab SJ, Bander SJ, Klahr S: Renal infection in autosomal dominant polycystic kidney disease. Am J Med 82: 714–718, 1987 https://doi.org/10.1016/0002-9343(87)90005-2
doi: 10.1016/0002-9343(87)90005-2
Sklar AH, Caruana RJ, Lammers JE, Strauser GD: Renal infections in autosomal dominant polycystic kidney disease. Am J Kidney Dis 10: 81–88, 1987 https://doi.org/10.1016/S0272-6386(87)80036-7
doi: 10.1016/S0272-6386(87)80036-7
Chow CL, Ong AC: Autosomal dominant polycystic kidney disease. Clin Med (Lond) 9: 278–283, 2009 https://doi.org/10.7861/clinmedicine.9-3-278
doi: 10.7861/clinmedicine.9-3-278
Idrizi A, Barbullushi M, Petrela E, Kodra S, Koroshi A, Thereska N: The influence of renal manifestations to the progression of autosomal dominant polycystic kidney disease. Hippokratia 13: 161–164, 2009
Ahmed ER, Tashkandi MA, Nahrir S, Maulana A: Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease. Saudi J Kidney Dis Transpl 17: 511–515, 2006
Hwang JH, Park HC, Jeong JC, Ha Baek S, Han MY, Bang K, Cho JY, Yu SH, Yang J, Oh KH, Hwang YH, Ahn C: Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol 14: 1, 2013 https://doi.org/10.1186/1471-2369-14-1
doi: 10.1186/1471-2369-14-1
Kuo IC, Lee JJ, Hwang DY, Lim LM, Lin HY, Hwang SJ, Chen HC, Hung CC: Pyuria, urinary tract infection and renal outcome in patients with chronic kidney disease stage 3-5. Sci Rep 10: 19460, 2020 https://doi.org/10.1038/s41598-020-76520-5
doi: 10.1038/s41598-020-76520-5